ATRA can stimulate MDSCs into mature myeloid cells40 and also decrease their immunosuppressive activities via ERK1/2 kinase pathway;41 however, ATRA simultaneously induces the expansion of Treg cells42, another important immune suppressive population, precluding ATRA from being a suitable anti-cancer drug. Here, MAPK3 is linked to cancer.